News from abbvie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

May 25, 2023, 08:45 ET New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease

AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL,...

May 24, 2023, 09:00 ET AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress

- Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ® (upadacitinib) and HUMIRA® (adalimumab), both in combination...

May 19, 2023, 12:34 ET EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only ...

May 18, 2023, 12:25 ET U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults

– The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by...

May 06, 2023, 07:30 ET AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie (NYSE: ABBV) today announced it will present 29 abstracts during the 2023 Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023, being...

May 02, 2023, 08:00 ET AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. Robert A. Michael, vice...

Apr 27, 2023, 07:32 ET AbbVie Reports First-Quarter 2023 Financial Results

Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent;...

Apr 21, 2023, 00:01 ET AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting

The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who...

Apr 17, 2023, 19:41 ET U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic...

Apr 17, 2023, 02:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease

– Seventh approved indication for RINVOQ in the European Union (EU) and the first and only oral Janus Kinase (JAK) inhibitor approved to treat adult...

Apr 12, 2023, 11:00 ET AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year

AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship, a program that is making a difference in the lives of young adults with CF...

Apr 04, 2023, 14:08 ET AbbVie avança estudo clínico de Fase 3 com upadacitinibe para tratamento de lúpus eritematoso sistêmico

Apr 04, 2023, 08:00 ET AbbVie to Host First-Quarter 2023 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. AbbVie will host a...

Mar 23, 2023, 09:00 ET AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic...

Mar 23, 2023, 08:30 ET Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

A significantly higher proportion of patients with moderately to severely active ulcerative colitis treated with risankizumab achieved the primary...

Mar 22, 2023, 08:45 ET AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application

AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug...

Mar 18, 2023, 10:03 ET AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy

Treatment with SKYRIZI (risankizumab) demonstrated short- and long-term efficacy of psoriasis signs and symptoms (sPGA 0/1) at week 16 and week 52 in ...

Mar 15, 2023, 08:03 ET AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema

AbbVie (NYSE: ABBV) today announced the launch of a new documentary film, "Under My Skin: Untold Stories of Life with Eczema," which debuted at South ...

Mar 13, 2023, 08:03 ET AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American Academy ...